| SYSTEMATIC REVIEW |
|
| Year : 2021 | Volume
: 12
| Issue : 1 | Page : 42 |
|
|
Effect of Vitamin D supplements on relapse rate and Expanded Disability Status Scale (EDSS) in multiple sclerosis (MS): A systematic review and meta-analysis
Sara Hanaei1, Mohammad Ali Sahraian2, Mehdi Mohammadifar3, Sreeram V Ramagopalan4, Mahsa Ghajarzadeh5
1 Research Center for Immunodeficiencies, Tehran University of Medical Sciences; Universal Scientific Education and Research Network, Tehran, Iran
2 Multiple Sclerosis Research Center, Neuroscience institute, Tehran University of Medical Sciences, Tehran, Iran
3 Department of Radiology, Zanjan University of Medical Sciences, Zanjan, Iran
4 F Hoffman-La Roche, Basel, Switzerland
5 Multiple Sclerosis Research Center, Neuroscience institute; Universal Council of Epidemiology, Universal Scientific Education and Research Network, Tehran University of Medical Sciences, Tehran, Iran
Correspondence Address:
Mahsa Ghajarzadeh
Neuroscience Institute, Imam Hospital, Tehran
Iran
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/ijpvm.IJPVM_208_20
|
|
|
Background: Multiple sclerosis (MS) is an inflammatory disease while there are controversies regarding the role of vitamin D supplements in controlling relapse and disability improvement during treatment. Objective: The goal of this systematic review and meta-analysis was to evaluate the effect of vitamin D supplements on MS-related relapse and the Expanded Disability Status Scale (EDSS). Methods: We searched databases to include randomized clinical trials (RCTs) which were published up to October 2018. We included RCTs, being single-blinded or double-blinded or open-label trials in which one of the main outcomes was EDSS and/or relapse after vitamin D supplementation. All statistical analyses were performed using RevMan 5.3. Odds ratios (OR) and 95% confidence intervals (CI) were calculated for relapse between treatment arms. The mean difference was calculated for EDSS comparisons. Results: Nine articles were included for analysis. Of these nine studies, five compared vitamin D supplement groups with placebo (group 1 studies), and four compared high- and low-dose vitamin D groups. A total of 561 patients were analyzed. Being treated with vitamin D instead of placebo showed no effect on relapse rate (OR = 0.66, 95% CI = 0.28–1.54) as well as EDSS (mean difference = 0.06, 95%CI [-0.31, 0.42]). The results of studies comparing high- vs. low-dose vitamin D interventions showed no significant effect on relapse rate (OR = 1.08, 95%CI [0.29–4.08] as well as final EDSS (mean difference = 0.17, 95% CI = -0.73, 1.07). Conclusions: Our findings show that vitamin D supplements (high or low dose) have no significant effect on relapse rate and disability during treatment in MS patients.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
